Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2003
08/07/2003CA2474447A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors
08/07/2003CA2474433A1 Arylsulfonamidobenzylic compounds
08/07/2003CA2474349A1 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same
08/07/2003CA2474316A1 Kappa-pviia-related conotoxins as organ protectants
08/07/2003CA2474306A1 Selective analgesic agents
08/07/2003CA2474000A1 Alpha 2 delta ligands to treat tinnitus
08/07/2003CA2473990A1 Modulation of type ii.beta. phosphoinositide phosphate kinase
08/07/2003CA2473810A1 Fgfr agonists
08/07/2003CA2473797A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
08/07/2003CA2473457A1 Cotherapy with an oxazolidinone and a vitamin b
08/07/2003CA2473158A1 Treatment of rheumatoid arthritis using imatinib
08/07/2003CA2473128A1 Genetic polymorphisms in the preprotachykinin gene
08/07/2003CA2472103A1 Transmucosal delivery of proton pump inhibitors
08/07/2003CA2466228A1 Method for treating diseases with omega interferon
08/07/2003CA2465265A1 Degp protease: cleavage site identification and proteolysis of a natural target in e. coli
08/07/2003CA2453770A1 Compositions for preventing human cancer and method of preventing human cancer
08/06/2003EP1332763A1 High-density lipoprotein-cholesterol level elevating agent
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332368A2 Methods for detecting the efficacy of anticancer treatments
08/06/2003EP1332366A1 Methods for the treatment of cellular proliferative disorders
08/06/2003EP1332363A1 Detection of neurodegenerative disorders
08/06/2003EP1332229A1 Method for screening agents capable of treating obesity
08/06/2003EP1332218A1 Differentiation-inducing substances
08/06/2003EP1332131A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1332129A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1331946A2 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
08/06/2003EP1331945A2 Otic microbial combinations for treatment of animals with ruptured tympanic membrane
08/06/2003EP1331940A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
08/06/2003EP1331937A2 Dibenzoxazepine alpha v integrin receptor antagonist
08/06/2003EP1331932A2 Therapeutic uses for ip 3? receptor-mediated calcium channel modulators
08/06/2003EP1331930A2 Methods and compositions for regulating memory consolidation
08/06/2003EP1331929A1 Transdermal drug delivery system with improved water absorbability and adhesion properties
08/06/2003EP1331927A1 Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
08/06/2003EP1331919A2 Dental composition for hypersensitive teeth
08/06/2003EP1331855A2 Aged companion pet diet
08/06/2003EP1244498B1 Combination of trimebutine with an opioid analgesic
08/06/2003EP1173187B1 Combined preparations comprising morpholine anthracyclines and platinum derivatives
08/06/2003EP1162945B1 Particle based vaccine composition
08/06/2003EP1126846B1 Use of a nicotine receptor agonist for the manufacture of a medicament for the treatment of obsessive compulsive disorder
08/06/2003EP1077684B1 Effervescent preparations
08/06/2003EP1030734B1 Encapsulate of active material in alginate matrix
08/06/2003EP0804419B1 Quinoline derivatives as tachykinin nk 3 receptor antagonists
08/06/2003CN1434865A Regulation effect of conjugated frame transport protein ABC1
08/06/2003CN1434832A DNA for encoding the RGI polypeptide
08/06/2003CN1434824A Bicyclic inhibitors of glycogen synthase kinase 3
08/06/2003CN1434817A Pyrazole cyclic AMP-specific PDE inhibitors
08/06/2003CN1434807A Pyrazine based inhibitors of glycogen synthase kinase 3
08/06/2003CN1434801A Substited 8-anylquinoline phosphodiesterase-4 inhibitors
08/06/2003CN1434798A Pyrrolidines which inhibit CAMP-specific PDE
08/06/2003CN1434797A Hydrazone and oxime derivatives of pyrrolidine as AMP-specific phosphodiesterase inhibitons
08/06/2003CN1434796A Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals
08/06/2003CN1434722A Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
08/06/2003CN1434718A Activation and inhibition of immune system
08/06/2003CN1434713A Sustained-release formulation of a cyclooxygenase-2 inhibitor
08/06/2003CN1434712A Nitrosated and nitrosylated cyclooxygenase-2 inhibitors compositions and methods of use
08/06/2003CN1434711A Use of substances that act as cascade inhibitors of the Raf/MEK/ERK signal cascade, for producing a medicament to treat dna and rna viruses
08/06/2003CN1434705A Use of hydroxide-releasing agents as skin permeation enhancers
08/06/2003CN1434691A Tissue sensitizing compounds for females and methods and apparatus for the delivery of these compounds
08/06/2003CN1117155C Novel compounds
08/06/2003CN1116899C Oral pharmaceutical dosage forms comprising a proton pump inhibitorand NSAID
08/06/2003CN1116870C Applicatino of preventing and treating peripheral neurophathy by administering selegiline
08/06/2003CN1116869C Use of THF-alpha-antagonist for treating neurogenic skin redness
08/05/2003US6603023 Synthesis of epothilones, intermediates thereto and analogues thereof
08/05/2003US6602888 Use of α1C specific compounds to treat benign prostatic hyperplasia
08/05/2003US6602881 Anti-inflammatory uses of manzamines
08/05/2003US6602870 Synergistic antitumor mixture of tegafur, uracil and folinic acid to potentiate coadministered oxaliplatin; colorectal cancer
08/05/2003US6602864 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
08/05/2003US6602664 3′-azido-2′,3′-dideoxyuridine in an anti-HIV effectiveness test protocol
08/05/2003US6602526 Anti-aging component containing methyltransferase and a carrier
08/05/2003US6602511 Lecithin, sphingolipid or galacto lipid hydrophobic surfactant and hydrophilic surfactant; oil in water emulsion; administering low water soluble drugs
08/05/2003US6602510 Eight isolated epitopes YLSGANLNV (SEQ ID NO:1), IMIGVLVGV (SEQ ID NO:2), KLBPVQLWV (SEQ ID NO:3), SMPPPGTRV (SEQ ID NO:4), KVAELVHFL (SEQ ID NO:5), YLQLVFGIEV (SEQ ID NO:6), RLLQETELV (SEQ ID NO:7), and, VVLGVVFGI (SEQ ID NO:8).
08/05/2003US6602509 Compound and method for the prevention and/or the treatment of allergy
08/05/2003US6602296 Chemical supplementation of bone
08/05/2003US6601580 Enhancing therapeutic effectiveness of nitric oxide inhalation
08/05/2003CA2419989A1 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
08/05/2003CA2275595C Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
08/01/2003CA2370396A1 Hepatitis c inhibitor tri-peptides
07/2003
07/31/2003WO2003062443A2 Novel substituted alkane compounds and uses thereof
07/31/2003WO2003062392A2 Methods of treating conditions associated with an edg receptor
07/31/2003WO2003062390A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
07/31/2003WO2003062274A1 Novel proteins and dnas thereof
07/31/2003WO2003062262A2 Modulation of heat-shock-protein-based immunotherapies
07/31/2003WO2003062204A1 Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
07/31/2003WO2003062200A2 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
07/31/2003WO2003062189A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
07/31/2003WO2003061713A1 Nsaid-containing topical formulations that demonstrate chemopreventive activity
07/31/2003WO2003061710A1 AGENT CONTROLLING THE APOPTOSIS INDUCTION BY p73
07/31/2003WO2003061706A1 A weight management system for obese animals
07/31/2003WO2003061705A1 Weight management system for obese animals
07/31/2003WO2003061704A2 Combination therapy for the treatment of bacterial infections
07/31/2003WO2003061703A1 Methods for treatment of multiple sclerosis with statins
07/31/2003WO2003061702A1 Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunsuppressor and anti-inflammatory agent
07/31/2003WO2003061698A1 6-fluorobicyclo[3.1.0]hexane derivatives
07/31/2003WO2003061696A2 Systems and methods for photodynamic therapy
07/31/2003WO2003061669A1 Use of alkylphosphocholines for the preventative treatment of protozoan diseases
07/31/2003WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies
07/31/2003WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases
07/31/2003WO2003061665A1 Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
07/31/2003WO2003061663A1 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia
07/31/2003WO2003061660A1 Melanocortin receptor agonists
1 ... 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 ... 1151